These are the guidelines on hepatitis B and C management for IUSTI/WHO in Europe, 2010. They describe the epidemiology, diagnosis, clinical features, treatment and prevention of hepatitis B and C with particular reference to sexual health clinical practice.
European Commission Health and Consumers Directorate General. Hepatitis B overview of epidemiology and disease burden of hepatitis B in the European region. See https://docs.google.com/fileview?id=0B1MhGB73moFKM2RmMmQxZDAtMjlkNy00OTg2LWIwNTQtNjMyNDFhMGZkMDQz&hl=en&authkey=CMyCytwE (last checked 15 November 2010)
2.
WHO Regional Office for Europe. Hepatitis B in the WHO European region 1990–2004. See http://data.euro.who.int/cisid/?TabID=253353 (last checked 15 Novermber 2010)
3.
World Health Organisation. Hepatitis B. See http://www.who.int/csr/disease/hepatitis/HepatitisB_whocdscsrlyo2002_2.pdf (last checked 15 Novermber 2010)
4.
RantalaM, van de LaarMJ. Surveillance and epidemiology of hepatitis B and C in Europe – a review. Euro Surveillance: Bull Eur Maladies Transmissibles = Eur Commun Dis Bull2008;13:1560
5.
UrbanusAT, van HoudtR, van de LaarTJ, CoutinhoRA. Viral hepatitis among men who have sex with men, epidemiology and public health consequences. Euro Surveillance: Bull Eur Maladies Transmissibles = Eur Commun Dis Bull2009;14:1560
6.
GilsonRJ, de RuiterA, WaiteJ, Hepatitis B virus infection in patients attending a genitourinary medicine clinic: risk factors and vaccination coverage. Sex Trans Inf1998;74:110–5
7.
WardH, DayS, WeberJ. Risky business: health and safety in the sex industry over a 9 year period. Sex Trans Infect1999;75:340–3
8.
HartGJ, DawsonJ, FitzpatrickRM, Risk behaviour, anti-HIV and anti-hepatitis B core prevalence in clinic and non-clinic samples of gay men in England, 1991–1992. AIDS1993;7:863–9
9.
DavisLG, WeberDJ, LemonSM. Horizontal transmission of hepatitis B virus. Lancet1989;i:889–93
10.
HoofnagleJH. Chronic hepatitis B. N Engl J Med1990;323:337–9
11.
OsellaAR, MassaMA, JoekesS, Hepatitis B and C virus transmission among homosexual men. Am J Gastroenterol1998;93:49–52
12.
StruveJ, GieseckeJ, LindhG, Heterosexual contact as a major route for transmission of acute hepatitis B amongst adults. J Infect1990;20:111–21
13.
BalogunMA, RamsayME, FairleyCK, CollinsM, HeptonstallJ. Acute hepatitis B infection in England and Wales: 1985–96. Epidemiol Infect1999;122:125–31
14.
HuoTI, WuJC, HuangYH, Evidence of transmission of hepatitis B to spouses from sequence analysis of the viral genome. J Gastroenterol Hepatol1998;13:1138–42
15.
HyamsKC, PhillipsIA, TejadaA. Hepatitis B in a highly active prostitute population: evidence for a low risk of antigenaemia. J Infect Dis1990;162:295–8
16.
Department of Health. Hepatitis B. In: Immunisation against infectious disease – ‘The Green Book’. See http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_108820.pdf (last checked 15 November 2010)
17.
PalmovichD, Crnjakovic-PalmovicJ. Prevention of hepatitis B virus (HBV) infection in health-care workers after accidental exposure: a comparison of two prophylactic schedules. Infection1993;21:42–5
18.
BrookMG, LeverAML, GriffithsP, Antenatal screening for hepatitis B is medically and economically effective in the prevention of vertical transmission: three years experience in a London hospital. Quart J Med1989;264:313–7
19.
CrampME, GrundyHC, PerinpanayagamRM, Seroprevalence of hepatitis B and C virus in two institutions caring for mentally handicapped adults. J Roy Soc Med1996;89:401–2
20.
KiireCF. The epidemiology and prophylaxis of hepatitis B in sub-Saharan Africa: a view from tropical and sub-tropical Africa. Gut1996;38(Suppl 2):S5–12
21.
McIntyreN. Clinical presentation of acute viral hepatitis. Br Med Bull1990;46:533–47
22.
HyamsKC. Risks ofchronicity following acute hepatitis B virus infection: a review. Clin Infect Dis1995;20:992–1000
23.
GitlinN. Hepatitis B: diagnosis, prevention and treatment. Clin Chem1997;43:1500–6
24.
HannHW, HanSH, BlockTM, Symptomatology and health attitudes of chronic hepatitis B patients in the USA. J Viral Hepat2008;15:42–51
25.
PungpapongS, KimWR, PoteruchaJJ. Natural history of hepatitis B virus infection: an update for clinicians. Mayo Clin Proc2007;82:967–75
26.
ThomasHC. Best practice in the treatment of chronic hepatitis B: a summary of the European Viral Hepatitis Educational Initiative (EVHEI). J Hepatol2007;47:588–97
27.
KumarM, ChauhanR, GuptaN, Spontaneous increases in alanine aminotransferase levels in asymptomatic chronic hepatitis B virus-infected patients. Gastroenterol2009;136:1272–80
28.
KrajdenM, McNabbG, PetricM. The laboratory diagnosis of hepatitis B virus. Can J Infect Dis Med Microbiol2005;16:65–72
29.
WeinbaumCM, WilliamsI, MastE, Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recommend Rep2008;57/RR-8:1–20
30.
SturrockCJ, CurrieMJ, VallyH, Community-based sexual health care works: a review of the ACT outreach program. Sex Health2007;4:201–4
31.
SethiG, HoldenBM, GreeneL, GaffneyJ, WardH. Hepatitis B vaccination for male sex workers: the experience of a specialist GUM service. Sex Transm Infect2006;82:84–5
32.
KoeneRP, GotzHM, VanJA, Significance of isolated antibody to hepatitis B core antigen in Dutch national vaccination campaign of behavioural high-risk groups. Epidemiol Infect2009;137:495–503
33.
ThioCL. Diagnosis, diagnostic tests and monitoring of hepatitis B virus in monoinfected and HIV-coinfected patients. Antivir Ther Lond2007;12(suppl 3):H25–31
34.
MathewJL, El DibR, MathewPJ, BoxallEH, BrokJ.Hepatitis B immunisation in persons not previously exposed to hepatitis B or with unknown exposure status. Cochrane Database Syst Rev2008;2:CD006481
35.
ButDY, LaiCL, LimWL, FungJ, WongDK, YuenMF. Twenty-two years follow-up of a prospective randomized trial of hepatitis B vaccines without booster dose in children: final report. Vaccine2008;26:6587–91
36.
KeeffeEB, DieterichDT, HanSHB, A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol2006;4:936–62
37.
PapatheodoridisGV, ManolakopoulosS, DusheikoG, ArchimandritisAJ. Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Lancet Infect Dis2008;8:167–78
38.
SanchezJ, GotuzzoE, EscamillaJ, Sexually transmitted infections in female sex workers: reduced by condom use but not by a limited periodic examination program. Sex Trans Dis1998;25:82–9
39.
PaitoonpongL, SuankratayC. Immunological response to hepatitis B vaccination in patients with AIDS and virological response to highly active antiretroviral therapy. Scand J Infect Dis2008;40:54–8
40.
de-Vries-SluijsTEMS, HansenBE, van-DoornumGJJ, A prospective open study of the efficacy of high-dose recombinant hepatitis B rechallenge vaccination in HIV-infected patients. J Infect Dis2008;197:292–4
41.
FonsecaMO, PangLW, de Paula CavalheiroN, Randomized trial of recombinant hepatitis B vaccine in HIV-infectedadult patients comparing a standard dose to a double dose. Vaccine2005;23:2902–8
42.
NystromJ, CardellK, BjornsdottirTB, FrydenA, HultgrenC, SallbergM. Improved cell mediated immune responses after successful re-vaccination of non-responders to the hepatitis B virus surface antigen (HBsAg) vaccine using the combined hepatitis A and B vaccine. Vaccine2008;26:5967–72
43.
CardellK, AkerlindB, SallbergM, FrydenA. Excellent response rate to a double dose of the combined hepatitis A and B vaccine in previous nonresponders to hepatitis B vaccine. J Infect Dis2008;198:299–304
44.
LoCM, LauGK, ChanSC, FanST, WongJ. Efficacy of a pre-S containing vaccine in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B. Am J Transplant2007;7:434–39
45.
PichicheroME. Improving vaccine delivery using novel adjuvant systems. Hum Vaccin2008;4:262–70
46.
RendiWP, ShouvalD, GentonB, Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine. Vaccine2006;24:2781–89
47.
KundiM. New hepatitis B vaccine formulated with an improved adjuvant system. Expert Rev Vaccines2007;6:133–40
48.
BeranJ. Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients. Exp Opin Biolog Ther2008;8:235–47
49.
van-der-SandeMAB, MendyM, WaightP, Similar long-term vaccine efficacy of two versus three doses of HBV vaccine in early life. Vaccine2007;25:1509–12
50.
MarsanoLS, WestDJ, ChanI, A two dose hepatitis B vaccine regimen: proof of priming and memory responses in young adults. Vaccine1998;16:624–9
51.
UralO, FindikD. The response of isolated anti-HBc positive subjects to recombinant hepatitis B vaccine. J Infect2001;43:187–90
52.
European Consensus Group on Hepatitis B Immunity. Are booster immunisations needed for lifelong hepatitis B immunity?Lancet2000;355:561–65
53.
Van-DammeP, VanHK. A review of the long-term protection after hepatitis A and B vaccination. Travel Med Infect Dis2007;5:79–84
54.
JackAD, HallAJ, MaineN, MendyM, WhittleHC. What level of hepatitis B antibody is protective?J Infect Dis1999;179:489–92
55.
AlfalehF, AlshehriS, AlansariS, Long-term protection of hepatitis B vaccine 18 years after vaccination. J Infect2008;57:404–09
56.
KeeffeEB, DieterichDT, HanSH, A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol2008;6:1315–41
57.
JafriSM, LokAS. Antiviral therapy for chronic hepatitis B. Clin Liver D2010;14:425–38
58.
LaiCL, GaneE, LiawYF, Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med2007;357:2576–88
59.
ChanHLY, HeathcoteEJ, MarcellinP, Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med2007;147:745–54
60.
McMahonMA, JilekBL, BrennanTP. The HBV drug entecavir effects on HIV-1 replication and resistance. N Engl J Med2007;356:2614–21
61.
TanJ, DegertekinB, WongSN, Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J Hepatol2008;48:391–98
62.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines:management of chronic hepatitis B. J Hepatol2009;50:227–42
63.
KeeffeEB, MarcellinP. New and emerging treatment of chronic hepatitis B. Clin Gastroenterol Hepatol2007;5:285–94
64.
HuiCK, ZhangHY, BowdenS, 96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B. J Hepatol2008;48:714–20
65.
McMahonM, JilekB, BrennanT, the HBV drug entecavir – effects on HIV replication and resistance. N Engl J Med2007;356:2614–21
66.
GazzardBG, BHIVA Treatment Guidelines Writing Group. British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med2008;9:563–608
67.
NueschR, AnanworanichJ, SrasuebkulP, Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection. AIDS2008;22:152–54
68.
SorianoV, VispoE, BottecchiaM, Management of hepatitis B virus co-infection on and off antiretroviral therapy. Curr HIV/AIDS Rep2008;5:86–93
69.
LowE, CoxA, AtkinsM, NelsonM. Telbivudine has activity against HIV-1. AIDS2009;23:546–47
70.
PetersMG, AndersenJ, LynchP, Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology2006;44:1110–16
71.
PramoolsinsapC. Acutehepatitis A and immunity to hepatitits A virus in hepatitis B virus carriers and in HBV- or hepatitis C virus-related chronic liver diseases in Thailand. J Viral Hepat2000;7:11–12
72.
GambarinGM. Hepatitis B in pregnancy. Clin Liver Dis2007;11:945–63
73.
XuWM, CuiYT, WangL, YangH, Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat2009;16:94–103
74.
VeldhuijzenIK, MesTH, MostertMC, An improved approach to identify epidemiological and phylogenetic transmission pairs of source and contact tracing of hepatitis B. J Med Virol2009;81:425–34
75.
ZuckermanJN. Review: hepatitis B immune globulin for prevention of hepatitis B infection. J Med Virol2007;79:919–21
76.
CrossTJS, RizziP, HornerM, The increasing prevalence of hepatitis delta virus (HDV) infection in South London. J Med Virol2008;80:277–82
77.
FarciP, ChessaL, BalestrieriC, SerraG, LaiME. Treatment of chronic hepatitis D. J Viral Hepat2007;14(suppl 1):58–63
78.
WHO. Hepatitis C prevalence 2007. See http://data.euro.who.int/cisid/?TabID=253353/ (last checked 15 Novermber 2010)
79.
WHO. Hepatitis C. See http://www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/index1.html (last checked 15 November 2010)
80.
DeP, RoyE, BoivinJF, CoxJ, MorissetteC. Risk of hepatitis C virus transmission through drug preparation equipment: a systematic and methodological review. J Viral Hepat2008;15:279–92
81.
PersicoM, PerrottaS, PersicoE, Hepatitis C virus carriers with persistently normal ALT levels: biological peculiarities and update of the natural history of liver disease at 10 years. J Viral Hepat2006;13:290–6
82.
MassardJ, RatziuV, ThabutD, Natural history and predictors of disease severity in chronic hepatitis C. J Hepatol2006;44(suppl):S19–24
83.
EstebanJI, SauledaS, QuerJ. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol2008;48:148–62
84.
ElderA, PatersonC. Sharps injuries in UK health care: a review of injury rates, viral transmission and potential efficacy of safety devices. Occup Med Lond2006;56:566–74
85.
SawayamaY, HayashiJ, KakudaK, Hepatitis C virus infection in institutionalized psychiatric patients: possible role of transmission by razor sharing. Digest Dis Sci2000;45:351–56
86.
McMahonJM, PougetER, TortuS. Individual and couple-level risk factors for hepatitis C infection among heterosexual drug users: a multilevel dyadic analysis. J Infect Dis2007;195:1572–81
87.
JebbariH, AlexanderS, WardH, Update on lymphogranuloma venereum in the United Kingdom. Sex Transm Infect2007;83:324–26
88.
DantaM, DusheikoGM. Acute HCV in HIV-positive individuals – a review. Curr Pharm Des2008;14:1690–97
89.
AkahaneY, KojimaM, SugaiY, Hepatitis C virus infection in spouses of patients with type C chronic liver disease. Ann Intern Med1994;120:748–52
90.
GiraudonI, RufM, MaguireH, Increase in newly acquired hepatitis C in HIV-positive men who have sex with men across London and Brighton 2002–2006: is this an outbreak?Sex Tansm Infect2008;84:111–15
91.
KaoJH, LiuCJ, ChenPJ, Low incidence of hepatitis C virus transmission between spouses: a prospective study. J Gastroenterol Hepatol2000;15:391–95
92.
MarincovichB, CastillaJ, del-RomeroJ, Absence of hepatitis C virus transmission in a prospective cohort of heterosexual serodiscordant couples. Sex Transm Infect2003;79:160–62
93.
TaylorA, HutchinsonSJ, GilchristG, CameronS, CarrS, GoldbergDJ. Prevalence and determinants of hepatitis C virus infection among female drug injecting sex workers in Glasgow. Harm Reduct J2008;5:11
94.
VescioMF, LongoB, BabudieriS, Correlates of hepatitis C virus seropositivity in prison inmates: a meta-analysis. J Epidemiol Commun Health2008;62:305–13
95.
MacíasJ, PalaciosRB, ClaroE, High prevalence of hepatitis C virus infection among non-injecting drug users: association with sharing the inhalation implements of crack. Liver Int2008;26:2
96.
ZhangT, LiY, HoWZ. Drug abuse, innate immunity and hepatitis C virus. Rev Med Virol2006;16:311–27
97.
IndolfiG, RestiM. Perinatal transmission of hepatitis C virus infection. J Med Virol2009;81:836–43
98.
McIntyrePG, ToshK, McGuireW.Caesarean section versus vaginal delivery for preventing mother to infant hepatitis C virus transmission. Cochrane Database Syst Rev2006;4:CD005546
99.
MastEE, HwangLY, SetoDSY, Risk factors for prenatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J Infect Dis2005;192:1880–9
100.
MokJ, PembreyL, TovoPA, NewellMLfor the European Paediatric Hepatitis C Virus Network. When does mother to child transmission of hepatitis C virus occur?Arch Dis Child2005;90:F156–60
101.
AzzariC, Moriond-M, IndolfiG, Higher risk of hepatitis C virus perinatal transmission from drug user mothers is mediated by peripheral blood mononuclear cell infection. J Med Virol2008;80:65–71
102.
PellicanoR, MladenovaI, DimitrovaSM, BrunoCM, SciaccaC, RizzettoM. The epidemiology of hepatitis C virus infection. An update for clinicians. Minerva Gastroenterol Dietol2004;50:1–7
103.
WangCC, KrantzE, KlarquistJ, Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors influencing viral clearance. J Infect Dis2007;196:1474–82
104.
LefilliatreP, VilleneuveJP. Fulminant hepatitis A in patients with chronic liver disease. Can J Public Health2000;91:168–70
105.
HarrisHE, EldridgeKP, HarbourS, AlexanderG, TeoCG, RamsayME. Does the clinical outcome of hepatitis C infection vary with the infecting hepatitis C virus type?J Viral Hepat2007;14:213–20
106.
KallmanJ, O-NeilMM, LariveB, Fatigue and health-related quality of life (HRQL) in chronic hepatitis C virus infection. Dig Dis Sci2007;52:2531–9
107.
SingalAK, AnandBS. Mechanisms of synergy between alcohol and hepatitis C virus. J Clin Gastroenterol2007;41:761–72
108.
StroffoliniT, SagnelliE, MarianoA, CraxíA, AlmasioP. Characteristics of HCV positive subjects referring to hospitals in Italy: a multicentre prevalence study on 6,999 cases. J Viral Hepat2006;13;351–54
109.
BrunoS, CrosignaniA, MaisonneuveP, Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study. Hepatology2007;46:1350–56
110.
KeWM, LiXJ, YuLN, Etiological investigation of fatal liver failure during the course of chronic hepatitis B in southeast China. J Gastroenterol2006;41:347–51
111.
HuiCK, ZhangHY, ShekT, Disease progression in Chinese chronic hepatitis C patients with persistently normal alanine aminotransaminase levels. Aliment Pharmacol Ther2007;25:1283–92
112.
ZeuzemS, AlbertiA, RosenbergW, Review article: management of patients with chronic hepatitis C virus infection and normal alanine aminotransferase activity. Aliment Pharmacol Ther2006;24:1133–49
113.
HadlichE, Alvares-Da-SilvaMR, Dal-MolinRK, ZenkerR, GoldaniLZ. Hepatitis C virus (HCV) viremia in HIV-infected patients without HCV antibodies detectable by third-generation enzyme immunoassay. J Gastroenterol Hepatol2007;22:1506–9
114.
ScottJD, GretchDR. Molecular diagnostics of hepatitis C virus infection: a systematic review. JAMA2007;297:724–32
115.
Abdel-HamidM, El-DalyM, El-KafrawyS, Comparison of second- and third-generation enzyme immunoassays for detecting antibodies to hepatitis C virus. J Clin Microbiol2002;40:1656–9
116.
SchutzbankTE, SefersSE, KahmannN, LiH, TangYW. Comparative evaluation of three commercially available methodologies for hepatitis C virus genotyping. J Clin Microbiol2006;44:3797–98
117.
ContrerasAM, TinocoE, CelisA, Hepatitis C antibody intra-assay correlation: is retest in duplicate necessary?Transfusion2007;47:1686–90
118.
PratiD. Transmission of hepatitis C virus by blood transfusions and other medical procedures: a global review. J Hepatol2006;45:607–16
119.
Van-Den-BergC, SmitC, Van-BrusselG, Coutinhol, PrinsM. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction2007;102:1454–62
120.
MateuGP, TreloarC, CalatayudVA, How can hepatitis C be prevented in the long term?. Int J Drug Policy2007;18:338–40
121.
WrightNMJ, TompkinsCNE. A review of the evidence for the effectiveness of primary prevention interventions for hepatitis C among injecting drug users. Harm Reduct J2006;3:27
122.
HorowitzB, BuschM. Estimating the pathogen safety of manufactured human plasma products: application to fibrin sealants and to thrombin. Transfusion2008;48:1739–53
123.
Friedrich–RustM, OngM. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology2008;134:960–974
124.
PaggiS, ColliA, FraquelliM, A non-invasive algorithm accurately predicts advanced fibrosis in hepatitis C: a comparison using histology with internal–external validation. J Hepatol2008;49:564–71
125.
CalleriG, CaritiG, GaiottinoF, A short course of pegylated interferon-alpha in acute HCV hepatitis. J Viral Hepat2007;14:116–21
126.
KamalSM, MoustafaKN, ChenJ, Duration of peginterferon therapy in acute hepatitis C: a randomized trial. Hepatology2006;43:923–31
127.
MatthewsGV, HellardM, HaberP, Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in Acute Hepatitis C. Clin Infect Dis2009;48:650–58
128.
BrokJ,, GluudLL, GluudC.Ribavirin plus interferon versus interferon for chronic hepatitis C. Cochrane Database Syst Rev2005;2:CD005445
129.
DeutschM, HadziyannisSJ. Old and emerging therapies in chronic hepatitis C: an update. J Viral Hepat2008;15:2–11
130.
ShepherdJ, JonesJ, HartwellD, DavidsonP, PriceA, WaughN. Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitisC: a systematic review and economic evaluation. Health Technol Assess2007;11:1–205
131.
DalgardO, BjøroK, RingLH, Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology2008;4:735–42
132.
MangiaA, MinervaN, BaccaD, Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial. Hepatology2008;47:43–50
133.
MangiaA, MinervaN, BaccaD, Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection. Hepatology2009;49:358–63
134.
KimAI, DornA, BouajramR, SaabS. The treatment of chronic hepatitis C in HIV-infected patients: a meta-analysis. HIV Med2007;8:312–21
135.
SorianoV, BarreiroP, Martin-CarboneroL. Update on the treatment of chronic hepatitis C in HIV-infected patients. AIDS Rev2007;9:99–113
136.
ShireNJ, WelgeJA, ShermanKE. Response rates to pegylated interferon and ribavirin in HCV/HIV coinfection: a research synthesis. J Viral Hepat2007;14:239–48
137.
LagunoM, CifuentesC, MurillasJ, Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatol2009;49:22–31
138.
LiawYF. Hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. J Gastroenterol2002;37(suppl 13):65–8
139.
BholaK, McGuireW. Does avoidance of breast feeding reduce mother-to-infant transmission of hepatitis C virus infection?Arch Dis Child2007;92:365–6
140.
ArraisTC, VanS, VandammeAM, Change in hepatitis C virus genotype in hemodialysis patients after end-of-treatment response to interferon monotherapy – relapse or re-infection?. J Med Virol2008;80:80–86
